Is KADCYLA right for you? Learn about the benefits and risks

If you have HER2-positive (HER2+) metastatic breast cancer and have been previously treated with Herceptin® (trastuzumab) and a taxane (chemotherapy), talk to your doctor to determine if KADCYLA is right for you.

Only women with HER2+ metastatic breast cancer can take KADCYLA

Because everyone is different, no one can say for sure if KADCYLA will work for you, or for how long it will keep working. 

  • KADCYLA has been studied only in women with HER2+ metastatic breast cancer. These women had already received Herceptin and a taxane (chemotherapy)
  • In this study, women took either KADCYLA or a combination of Tykerb® (lapatinib)* and Xeloda® (capecitabine) 

KADCYLA helped women live longer

  • In a clinical study, women taking KADCYLA lived nearly 6 months longer (30.9 months), on average, than women taking the combination of Tykerb and Xeloda (25.1 months)

KADCYLA made cancer stop growing and spreading for a longer time

  • In a clinical study, women taking KADCYLA lived without their cancer growing and spreading for longer (9.6 months), on average, than women taking the combination of Tykerb and Xeloda (6.4 months)

Side effects may occur with KADCYLA

What are the most serious side effects of KADCYLA?

KADCYLA is not the same medicine as trastuzumab (Herceptin). KADCYLA can cause severe liver problems that can be life-threatening. KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects.

Other possible serious side effects of KADCYLA include: lung problems, infusion-related reactions, serious bleeding, low platelet count, nerve damage, and skin reactions around the infusion site.

See additional information on these side effects below or talk to your doctor.

What are the most common side effects of KADCYLA?

The most common side effects seen in people taking KADCYLA were:

  • Tiredness
  • Nausea
  • Pain that affects the bones, muscles, ligaments, and tendons
  • Bleeding
  • Low platelet count
  • Headache
  • Liver problems
  • Constipation
  • Nosebleeds

Hair loss was not common in either study group

  • Less than 6% of women who took KADCYLA or lapatinib and capecitabine lost their hair (3.9% in the KADCYLA arm and 5.1% in the lapatinib and capecitabine arm)

*Tykerb is a registered trademark of GlaxoSmithKline.

Ask your healthcare team

See some questions you may want to discuss with your doctor.


HERConnection Program

A free program that provides information and resources to patients receiving KADCYLA.